Internal Medicine, Pulmonary Disease · Philadelphia, PA
NPI
1073774857
Since 2008
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
834 Walnut St Ste 650
Philadelphia, PA, 19107
Phone (215) 955-5161
Medicare paid, 2024
$8,408
124 services
Medicare patients, 2024
104
Average age 73
Drug cost, 2024
$1.9M
1,406 prescriptions
Company payments, 2025
$0
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jessica F Most was code 99214 (office e&m - established), 48 times for 48 patients. In total Jessica F Most billed 124 services in 17 codes, and Medicare paid $8,408.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-03-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 48 | 48 | $47.35 | $2,273 |
| 99214 Office E&M - Established | Office | 17 | 17 | $64.86 | $1,103 |
By year: 2022 $61K for 771 services; 2023 $77K for 838 services; 2024 $8,408 for 124 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jessica F Most prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 182 prescriptions and refills. In total Jessica F Most wrote 1,406 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 182 | 311 | 57 | $195K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 125 | 155 | 58 | $5,525 |
| Montelukast Sodium Generic | 79 | 201 | 40 | $902 |
| Dupixent Pen Dupilumab | 78 | 81 | 20 | $291K |
| Azithromycin Generic | 69 | 89 | 28 | $1,019 |
| Tezspire Tezepelumab-Ekko | 68 | 68 | 12 | $280K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 62 | 78 | 19 | $49K |
| Fasenra Pen Benralizumab | 55 | 94 | 15 | $307K |
| Breo Ellipta Fluticasone/Vilanterol | 53 | 83 | 24 | $32K |
| Spiriva Respimat Tiotropium Bromide | 47 | 55 | 19 | $28K |
| Symbicort Budesonide/Formoterol Fumarate | 36 | 60 | 18 | $14K |
| Advair Diskus Fluticasone Propion/Salmeterol | 30 | 38 | Under 11 | $8,429 |
| Dupixent Syringe Dupilumab | 30 | 34 | Under 11 | $128K |
| Fluticasone Propionate Generic | 30 | 60 | 17 | $467 |
| Nucala Mepolizumab | 27 | 27 | Under 11 | $247K |
Brand drugs: 968 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jessica F Most $0 (- in general payments such as food, travel and fees) from 1 company.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.